The Medical Letter on Drugs and Therapeutics
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| The Medical Letter on Drugs and Therapeutics | |
|---|---|
| Abbreviated title | Med Lett Drugs Ther |
| Discipline | Publication |
| Language | English, French, Italian, Chinese, and Spanish |
| Publication details | |
| Publisher | The Medical Letter, Inc. (USA) |
| Publication history | first published 1959 |
| Indexing | |
| ISSN | 1523-2859}} |
| Links | |
The Medical Letter on Drugs and Therapeutics, commonly referred to simply as The Medical Letter, provides independent, unbiased critical evaluations of new drugs and sometimes older drugs when important new information becomes available. The Medical Letter is well known as the "Gold Standard" within the medical community for new drug review.
The Medical Letter has a print and electronic circulation of well over 450,000 subscribers in 88 countries worldwide.
Published biweekly (26 issues/year), the newsletter is available in several languages: English (US and Canadian editions), French (Canadian and European editions), Italian, Chinese, and Spanish.The Medical Letter is also available as an electronic site license for institutions such as medical schools, hospitals and group practices.
The Medical Letter is published by The Medical Letter, Inc., which also publishes the monthly Treatment Guidelines from The Medical Letter.
Editorial Process
An expert consultant or one of the editors prepares the preliminary draft using both published and available unpublished studies that are carefully examined, paying special attention to the results of well controlled clinical trials.
The preliminary draft is edited and sent to every member of the Advisory Board, to 10-20 other investigators who have clinical and experimental experience with the drug or type of drug or disease under review, to the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC), to the first authors of all the articles cited in the text, to appropriate agents of the pharmaceutical companies making the drugs under review, and to drug companies that make similar compounds.
Many critical observations, suggestions and questions are received from the reviewers and are incorporated into the article during the revision process, and the article is checked and edited to make sure the final appraisal is not only accurate, but also easy to read.
flowchart of the editorial process
External links
The Medical Letter Editorial and Advisory Board
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
